Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
almonertinib + pemetrexed + cisplatin
- Development stage
- Phase 3
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of almonertinib (a third-generation EGFR tyrosine kinase inhibitor), pemetrexed (a multitargeted antifolate cytotoxic chemotherapy agent), and cisplatin (a platinum-based chemotherapy drug). This regimen is being investigated for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The combination aims to leverage both targeted therapy through EGFR inhibition and cytotoxic effects of chemotherapy to improve treatment outcomes.
02
Targets
DNADHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on almonertinib + pemetrexed + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on almonertinib + pemetrexed + cisplatin.